BCL2L10 and ovarian cancer: As Bcl2l10 is highly expressed in the ovary (Guillemin et al., 2009; Inohara et al., 1998), we can assume that the reduction of IRBIT expression in the ovarian cancer cell line leads to an increased activity of Bcl2l10, which may contribute to the usual resistance of cancer cells to apoptosis.